HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation

HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation

Abstract Background Pancreatic ductal adenocarcinoma (PDAC) represents an unmet clinical need due to the very poor prognosis and the lack of effective therapy. Here we investigated the potential of domatinostat (4SC-202), a new class I histone deacetylase (HDAC) inhibitor, currently in clinical deve...

Full description

Bibliographic Details
Main Authors: Maria Serena Roca, Tania Moccia, Federica Iannelli, Cristina Testa, Carlo Vitagliano, Michele Minopoli, Rosa Camerlingo, Giulia De Riso, Rossella De Cecio, Francesca Bruzzese, Mariarosaria Conte, Lucia Altucci, Elena Di Gennaro, Antonio Avallone, Alessandra Leone, Alfredo Budillon
Format: Article
Language:English
Published: BMC 2022-03-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
HDAC inhibitors
Domatinostat
Drug resistance
FOXM1
Cancer stem cells
Stress adaptation
Online Access:https://doi.org/10.1186/s13046-022-02295-4

Internet

https://doi.org/10.1186/s13046-022-02295-4

Similar Items